ReviewCancer medicine2019
Hope and challenge: Precision medicine in bladder cancer.
Review in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Integrated Genomic and Single-Cell Analysis Reveals Heterogeneity, Prognosis, and Treatment Vulnerability in Urothelial Carcinoma.Human mutation · 2026Article
- Integrating transcriptomics, single-cell omics, and deep learning-based histopathological features to identifyTranslational andrology and urology · 2025Article
- Prediction of response to neoadjuvant chemotherapy in patients with muscle-invasive urothelial bladder cancer: role of immune-related gene expression.Cancer immunology, immunotherapy : CII · 2025Article
- Predicting survival in bladder cancer with a novel apoptotic gene-related prognostic model.Discover oncology · 2024Article
- Investigation toward the economic feasibility of personalized medicine for healthcare service providers: the case of bladder cancer.Frontiers in medicine · 2024Article
- Single cell RNA-Sequencing Reveals Mast Cells Enhance Mononuclear Phagocytes Infiltration in Bladder Cancer Microenvironment.Journal of Cancer · 2024Article
- Metabolomic Signatures of Treatment Response in Bladder Cancer.International journal of molecular sciences · 2023Review
- Sustained release of therapeutic gene by injectable hydrogel for hepatocellular carcinoma.International journal of pharmaceutics: X · 2023Article
- Integrated multiomics analysis of chromosome 19 miRNA cluster in bladder cancer.Functional & integrative genomics · 2023Article
- Self-polymerized platinum (II)-Polydopamine nanomedicines for photo-chemotherapy of bladder Cancer favoring antitumor immune responses.Journal of nanobiotechnology · 2023Article
- Hsa_circ_0008035 Knockdown Inhibits Bladder Cancer Progression through miR-1184/RAP2B Axis.Urologia internationalis · 2023Article
- Cancer-Associated Membrane Protein as Targeted Therapy for Bladder Cancer.Pharmaceutics · 2022Review
- Predicting Recurrence of Non-Muscle-Invasive Bladder Cancer: Current Techniques and Future Trends.Cancers · 2022Review
- Interaction between HER2 and ATM predicts poor survival in bladder cancer patients.Journal of cellular and molecular medicine · 2022Article
- New bladder cancer non-invasive surveillance method based on voltammetric electronic tongue measurement of urine.iScience · 2022Article
- Article
- Concise synthesis and biological activity evaluation of novel pyrazinyl-aryl urea derivatives against several cancer cell lines, which can especially induce T24 apoptotic and necroptotic cell death.RSC medicinal chemistry · 2022Article
- Anti-tumor effect of trametinib in bladder cancer organoid and the underlying mechanism.Cancer biology & therapy · 2021Article
- Role of Exosomal miRNA in Bladder Cancer: A Promising Liquid Biopsy Biomarker.International journal of molecular sciences · 2021Review
- Quinazoline Derivatives as Potential Therapeutic Agents in Urinary Bladder Cancer Therapy.Frontiers in chemistry · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder cancer (BC) is a complex disease and could be classified into nonmuscle-invasive BC (NMIBC) or muscle-invasive BC (MIBC) subtypes according to the distinct genetic background and clinical prognosis. Until now, the golden standard and confirmed diagnosis of BC is cystoscopy and the major problems of BC are the high rate of recurrence and high costs in the clinic. Recent molecular and genetic studies have provided perspectives on the novel biomarkers and potential therapeutic targets of BC. In this article, we provided an overview of the traditional diagnostic approaches of BC, and introduced some new imaging, endoscopic, and immunological diagnostic technology in the accurate diagnosis of BC. Meanwhile, the minimally invasive precision treatment technique, immunotherapy, chemotherapy, gene therapy, and targeted therapy of BC were also included. Here, we will overview the diagnosis and therapy methods of BC used in clinical practice, focusing on their specificity, efficiency, and safety. On the basis of the discussion of the benefits of precision medicine in BC, we will also discuss the challenges and limitations facing the non-invasive methods of diagnosis and precision therapy of BC. The molecularly targeted and immunotherapeutic approaches, and gene therapy methods to BC treatment improved the prognosis and overall survival of BC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.